ホーム>>Peptides>>Angiotensin II (5-8) (human, rat, mouse)

Angiotensin II (5-8) (human, rat, mouse)

カタログ番号GC42810

アンギオテンシン II (5-8) (ヒト、ラット、マウス) は、ペプチド血管収縮剤アンギオテンシン II の内因性 C 末端フラグメントです。

Products are for research use only. Not for human use. We do not sell to patients.

Angiotensin II (5-8) (human, rat, mouse) 化学構造

Cas No.: 34233-50-6

サイズ 価格 在庫数
1mg
$135.00
Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Video Related Products

Angiotensin II (5-8) is an endogenous C-terminal fragment of the peptide vasoconstrictor angiotensin II . It inhibits renin release from rat kidney slices at a concentration of 50 μM and relaxes rat aorta pre-contracted with phenylephrine . In vivo, microinjection of angiotensin II (5-8) into the ventrolateral periaqueductal gray (vlPAG) of rats increases mean arterial pressure (MAP) and decreases heart rate (HR) by approximately 2.7- and 3-fold less, respectively, than angiotensin II. It increases the latency to withdrawal in a tail-flick test and the mechanical withdrawal threshold in an incision allodynia test in rats when administered at a dose of 0.2 nmol into the vlPAG. Angiotensin II (5-8) (0.4 nmol, vlPAG microinjection) reduces the number of entries and time spent in the open arms of the elevated plus maze and increases the mean startle amplitude, a measure of conditioned fear, in response to foot shock.

レビュー

Review for Angiotensin II (5-8) (human, rat, mouse)

Average Rating: 5 ★★★★★ (Based on Reviews and 29 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Angiotensin II (5-8) (human, rat, mouse)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.